AI
Tuesday, April 25, 2017 5:45:21 PM
> what you mean by "the original fibrosis/cirrhosis argument."
> reluctant to treat non-cirrhotic patients who have advanced fibrosis using a regimen that hasn't been shown to work in cirrhotic patients
Yes! That was my (unspoken) hypothesis.
To go into more detail: We do not know yet, how efficient the JNJ/ACHN's regimen will be in cirrhotic patients. But we know a) they need all 3 drugs and b) the dosis appears to be already "maxed out" and cannot be increased (except in terms of duration of treatment) due to safety concerns*.
As well, if I see correctly, cirrhotic patients are mentioned in this new trial only and they will be treated probably only contingent on the non-cirrhotic results (cf. description: "Participants will receive AL-335 800 milligram (mg)+ODV 25 mg+SMV 75 mg once daily for 8 weeks in Cohort 2. Dosing in cohort 2 will be started according to decision of Data Review Committee (DRC).", source https://clinicaltrials.gov/ct2/show/NCT02993250)
Well, this will be the interesting aspect to look at later
* see old posts here
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=125054560
http://investorshub.advfn.com/boards/replies.aspx?msg=125054944
> reluctant to treat non-cirrhotic patients who have advanced fibrosis using a regimen that hasn't been shown to work in cirrhotic patients
Yes! That was my (unspoken) hypothesis.
To go into more detail: We do not know yet, how efficient the JNJ/ACHN's regimen will be in cirrhotic patients. But we know a) they need all 3 drugs and b) the dosis appears to be already "maxed out" and cannot be increased (except in terms of duration of treatment) due to safety concerns*.
As well, if I see correctly, cirrhotic patients are mentioned in this new trial only and they will be treated probably only contingent on the non-cirrhotic results (cf. description: "Participants will receive AL-335 800 milligram (mg)+ODV 25 mg+SMV 75 mg once daily for 8 weeks in Cohort 2. Dosing in cohort 2 will be started according to decision of Data Review Committee (DRC).", source https://clinicaltrials.gov/ct2/show/NCT02993250)
Well, this will be the interesting aspect to look at later
* see old posts here
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=125054560
http://investorshub.advfn.com/boards/replies.aspx?msg=125054944
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
